BSC
PLX icon

BOLTON SECURITIES CORPORATION’s Protalix BioTherapeutics PLX Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$85.7K Hold
31,060
– – ﹤0.01% 1174
2026
Q2 		$72.4K Hold
31,060
– – ﹤0.01% 1201
2026
Q1 		$67.4K Buy
+31,060
New +$77.1K ﹤0.01% 1150
2025
Q3 		$69K Buy
+31,060
New +$50.6K ﹤0.01% 1070
2025
Q1 		$35.8K Buy
+14,000
New +$33.4K ﹤0.01% 1133

Other funds holding PLX

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's PLX Position: Q3 2026 in Review

BOLTON SECURITIES CORPORATION held its Protalix BioTherapeutics (PLX) position steady in Q3 2026 at 31,060 shares worth $85.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1174.

BOLTON SECURITIES CORPORATION first reported a position in PLX in Q1 2025 and has held it in 5 quarters since. 56 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • BOLTON SECURITIES CORPORATION held 31,060 shares of Protalix BioTherapeutics worth $85.7K as of Q3 2026.
  • BOLTON SECURITIES CORPORATION left its Protalix BioTherapeutics share count unchanged in Q3 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of BOLTON SECURITIES CORPORATION's portfolio in Q3 2026, its #1174 holding.
  • BOLTON SECURITIES CORPORATION first reported a position in Protalix BioTherapeutics in Q1 2025 and has held it in 5 quarters since.
  • 56 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q3 2026, filed 12 Nov 2026.